Stockscreener 앱 받기
6.71
7.70%
-0.56
전일 마감가:
$7.27
열려 있는:
$7.21
하루 거래량:
1.92M
Relative Volume:
0.66
시가총액:
$390.11M
수익:
$11.13M
순이익/손실:
$-114.59M
주가수익비율:
-2.901
EPS:
-2.313
순현금흐름:
$-113.96M
1주 성능:
-14.30%
1개월 성능:
-21.61%
6개월 성능:
-80.60%
1년 성능:
+8.93%
1일 변동 폭
$6.68
$7.25
1주일 범위
$6.47
$7.81
52주 변동 폭
$2.96
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.71 | 390.11M | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-14 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2026-09-01 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2026-08-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2026-08-14 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2026-07-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-07-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2026-07-30 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2026-07-30 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2026-07-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2026-07-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2026-07-28 | 다운그레이드 | Alliance Global Partners | Buy → Neutral |
| 2026-07-27 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2026-07-27 | 다운그레이드 | Roth Capital | Buy → Neutral |
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Millennium Management Trims Capricor Therapeutics (CAPR) Stake b - GuruFocus
Voting power over 1.67M Capricor (CAPR) shares is shared by three reporting parties. - Stock Titan
Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy — Experts And Investors Weigh In - Stocktwits
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular DystrophySlideshow (NASDAQ:CAPR) 2026-10-13 - Seeking Alpha
Analysts Expect Breakeven For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Before Long - Simply Wall Street
Capricor reports 24-month data for Duchenne therapy deramiocel By Investing.com - Investing.com South Africa
What's Going On With Capricor Therapeutics Stock Monday? - Benzinga
Capricor Therapeutics (CAPR) Shares Drop 10% Despite Positive Du - GuruFocus
H.C. Wainwright Sees Mixed Signals in Capricor Therapeutics (CAP - GuruFocus
Capricor drops as deramiocel OLE data fails to quell regulatory concerns - Seeking Alpha
Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November - Yahoo Finance
Roth Capital Maintains Neutral on Capricor Therapeutics (CAPR) A - GuruFocus
Capricor Therapeutics (CAPR) Reports Positive HOPE-3 Study Data on Deramiocel for Duchenne Muscular Dystrophy - GuruFocus
Capricor reports 24-month data for Duchenne therapy deramiocel - Investing.com
Capricor Therapeutics Reports Positive 24-Month HOPE-3 Data for Deramiocel in Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress - Yahoo Finance
After a year on placebo, patients’ arm-function decline rate was 76% lower on treatment - Stock Titan
Capricor Therapeutics, Inc. (CAPR) - Yahoo! Finance Canada
Capricor Therapeutics, Inc. (CAPR) - Yahoo! Finance Canada
Small-Cap Biotech Capricor Therapeutics (CAPR) Sees Elevated Sho - gurufocus.com
Capricor Therapeutics Shares Jump as Two-Year Data Bolster Duchenne Drug Case - finance.biggo.com
CAPR Stock Jumps As Analysts Hike Price Targets Into FDA Date - StocksToTrade
Capricor Therapeutics Stock Surges: What's Going On? - Benzinga
CAPR Stock Pops As Analysts Hike Targets Ahead FDA Call - timothysykes.com
CAPR Stock Jumps As Analysts Hike Price Targets Ahead FDA Call - StocksToTrade
CAPR Stock Jumps As Analysts Hike Targets Ahead Of FDA Date - timothysykes.com
CAPR Stock Jumps As Street Hikes Price Targets Into FDA Catalyst - StocksToTrade
Capricor Therapeutics, Inc. stock Analysis: Bearish Trend and Intraday Pause - The Cryptonomist
Capricor Therapeutics (CAPR) Shares Surge on Positive Phase 3 Da - gurufocus.com
Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ) - Seeking Alpha
Total equity of Capricor Therapeutics, Inc. – HAN:4LN2 - TradingView
Return on equity % of Capricor Therapeutics, Inc. – HAN:4LN2 - TradingView
Recover Investment Losses: Class Action Initiated Against Capricor Therapeutics, Inc. (CAPR) - ACCESS Newswire
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - 巴士的報
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - Bluefield Daily Telegraph
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - globenewswire.com
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline - PR Newswire
CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - PR Newswire
CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Action - TMX Newsfile
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. - GlobeNewswire
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - GlobeNewswire Inc.
CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - GlobeNewswire Inc.
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 28, 2026Contact Levi & Korsinsky - ACCESS Newswire
Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 | FinancialContent - FinancialContent
CAPRICOR DEADLINE SEPTEMBER 28th: Bragar Eagel & Squire, - globenewswire.com
CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - Eastern Progress
CAPR Stock On Track For Worst Week Ever After Regulatory Setback For DMD Therapy - stocktwits.com
Capricor Therapeutics Shareholder Alert: ClaimsFiler - globenewswire.com
SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026CAPR - PR Newswire
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Capricor Therapeutics Inc 주식 (CAPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
11,223 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Option Exercise |
3.18 |
24,100 |
76,638 |
35,323 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
11,223 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
11,623 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
30,947 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
11,723 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
31,047 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
30,547 |
4.22%
자본화:
|
볼륨(24시간):